Verdant PhytoMed (Pty) Ltd Business Plan › Section 3 › Industry & Market Analysis

3.1 Global Medicinal Cannabis Market

The global medicinal cannabis industry has undergone a fundamental transformation over the past decade, transitioning from a nascent, stigmatised sector to a mainstream pharmaceutical category with robust regulatory frameworks across more than 50 countries. According to industry research, the global medicinal cannabis market was valued at approximately USD 12.6 billion in 2023 and is projected to reach USD 40 billion by 2032, representing a CAGR of approximately 14%.

Key demand drivers include the growing clinical evidence base for cannabis-derived treatments in chronic pain management, epilepsy (particularly refractory paediatric epilepsy), oncology-related symptoms (nausea, appetite loss, pain), multiple sclerosis spasticity, and anxiety disorders. The shift toward plant-based and natural pharmaceutical alternatives, coupled with increasing physician acceptance and patient demand, underpins sustained market growth.

Market Size by Region (2023 vs. 2032 Projected)

3.2 European Market — Primary Target

Europe represents the most attractive export market for South African medicinal cannabis producers. Germany alone has emerged as the world’s largest regulated medicinal cannabis import market, with patient numbers exceeding 300,000 and growing. The German market was valued at approximately EUR 500 million in 2024, with projections of EUR 2 billion by 2030. Other key European markets include the United Kingdom (post-2018 legalisation), Italy, the Netherlands, Poland, and the Czech Republic.

The European market’s attractiveness for South African producers stems from three factors: (i) the EU-GMP import framework which enables non-EU producers with certified facilities to supply the market directly; (ii) the chronic undersupply of pharmaceutical-grade cannabis relative to growing patient demand; and (iii) favourable trade relationships under the EU-South Africa Trade, Development and Cooperation Agreement.

3.3 South African Regulatory Environment

Medicinal cannabis in South Africa is regulated under the Medicines and Related Substances Act 101 of 1965, as administered by the South African Health Products Regulatory Authority (SAHPRA). Cannabis remains classified as a Schedule 6 substance for medicinal purposes and Schedule 7 for recreational use. Cultivation, processing, and distribution of medicinal cannabis requires a Section 22C permit issued by SAHPRA.

Key Regulatory Requirements

• SAHPRA Section 22C licence for cultivation and processing of cannabis for medicinal or research purposes

• Compliance with Good Agricultural and Collection Practice (GACP) standards for cultivation

• EU-GMP certification for processing facilities intended to supply European markets

• Department of Agriculture, Land Reform and Rural Development (DALRRD) permits for agricultural operations

• South African Police Service (SAPS) security clearance for all directors, key personnel, and the facility

• Department of Health import/export permits for international trade in controlled substances

• Environmental Impact Assessment (EIA) approval under the National Environmental Management Act

Competitive Landscape

As of 2025, approximately 114 licensed medicinal cannabis operators are active in South Africa, though the majority remain in early-stage development or pre-revenue. Fewer than 15 operators have achieved EU-GMP certification, and fewer than 10 have executed meaningful export contracts. This creates a significant first-mover advantage for well-capitalised, compliance-focused entrants such as Verdant PhytoMed.

3.4 South Africa’s Competitive Advantage

This document contains proprietary and confidential information. Distribution without written consent is prohibited.